Bayer face shareholder reckoning over Monsanto deal as cancer lawsuits mount

German pharmaceutical giant Bayer is running into mounting shareholder opposition ahead of its annual meeting on Friday. The company’s investors are faulting management for failing to foresee the risks of its biggest deal ever.

A growing number of shareholders have said they won’t support executives and supervisory board members in the upcoming no-confidence vote. The vote has no legal weight but a low enough approval rating could be risky for the future of CEO Werner Baumann and other managers who were in charge of the $63 billion acquisition of US agriculture giant Monsanto.